Gyros appoints Dr. Jack Johansen and Mr. Lars Eric Utterman as Non-executives Directors to the Board of Directors

07-Jul-2009

Gyros AB, the leading provider of automated micro-immunoassays for therapeutic protein development, has appointed Dr. Jack Johansen and Mr. Lars Eric Utterman as Non-executive Directors to its Board of Directors. These appointments bring significant executive and board level experience for the development and commercialization of novel technologies used in biopharmaceutical discovery and development. The appointments follow the recent completion of a successful equity fundraising that saw the company raise SEK 80 million (approximately €7.4m) from its existing investors to drive the further commercialization of its technology.

Jack Johansen is as an executive consultant to various life science/venture capital companies, including Novo A/S. From 1995-2001, he was a founding CEO of two life science diagnostic companies, Boston Biosystems, Inc. and Boston Probes, Inc., both of which were sold. Prior to this, he was Executive Vice President of science and technology at Millipore Corporation and President of Millicorp, which is Millipore’s venture fund. Dr. Johansen is Chairman of the Board of Directors of Protein Forest, Inc. and AdvanDx Inc. and serves on the Board of Directors of Symphogen A/S and 7TM A/S.

Lars Eric Utterman is Chairman of the board of Ludesi AB and Cellectricon AB and board member of LIVC Technologies GmbH. As an executive consultant he was engaged by Gyros during 2008 and now serves as interim manager of IonGate Biosciences GmbH. He has held a number of executive positions at international level for more than 30 years with GE Healthcare, Amersham, Pharmacia and Boehringer Mannheim (now Roche Diagnostics).

Per Carendi, Chairman of Gyros and CEO of SLS Invest, its lead investor, said, “I am pleased Jack and Lars are joining the Gyros board and very much look forward to Gyros benefiting from their experience and expertise in developing and commercializing technologies for the life sciences industry. Their contribution will be crucial as we look to drive the further commercialization of our Gyrolab platform for accelerating the development of therapeutic proteins.”


Enquiries:
For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com
www.zymecommunications.com


Notes to editors:
About Gyros (www.gyros.com)

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.